Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) announced on May 1, 2026 the grant of inducement stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan.
The company granted options to 17 non-executive employees for an aggregate of 731,000 shares, at a per‑share exercise price of $1.52 (closing price on the grant date). Each option vests over four years (25% after one year, then monthly) and has a 10‑year term, subject to the plan and continued service.
AI-generated analysis. Not financial advice.
Positive
- 731,000 options granted (May 1, 2026)
- Grants align with Nasdaq Rule 5635(c)(4) and company plan
- Standard four‑year vesting with 25% one‑year cliff
Negative
- Options create potential for share count increase of 731,000
- Exercise price equals recent closing price ($1.52) so no immediate cash inflow
News Market Reaction – IVVD
On the day this news was published, IVVD declined 5.44%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $25M from the company's valuation, bringing the market cap to $435.52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IVVD showed a -3.29% move while peers were mixed: AVIR, CADL, and LYEL were up (up to +14.61%), NMRA and TNXP were down. Momentum scanners flagged NMRA and LXEO moving up, which does not align cleanly with IVVD’s downside, suggesting a more stock-specific backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Conference participation | Neutral | -3.5% | Chairman speaking at POLITICO Health Care Summit on viral disease prevention. |
| Apr 09 | Pipeline progress | Positive | +31.9% | Phase 3 DECLARATION trial upsized and measles mAb VMS063 advanced toward IND. |
| Apr 07 | Education campaign | Neutral | -0.8% | Launch of “Antibodies for Any Body” immune health education campaign with Lindsey Vonn. |
| Apr 06 | Inducement grants | Neutral | +1.6% | Inducement stock options to 16 new hires under 2026 Inducement Plan and Nasdaq rules. |
| Mar 30 | Scientific presentation | Positive | +9.2% | CSO presentation on mAb therapies and Invivyd’s platform at World Vaccine Congress. |
Recent IVVD news has often produced aligned price reactions, with positive clinical and presentation updates seeing upside and neutral corporate or HR items having modest impact. A prior inducement grant announcement in early April 2026 coincided with a small positive move, suggesting these HR-related updates have not historically driven large dislocations.
Over the last few months, Invivyd has balanced corporate visibility, pipeline advancement, and routine HR-related grants. In March–April 2026 it highlighted scientific talks at the World Vaccine Congress and a POLITICO Health Care Summit, and advanced its measles mAb candidate VMS063 with promising in vitro data, which drew a strong +31.85% reaction on April 9. By contrast, educational campaigns and inducement option grants, including a similar grant disclosure on April 6, have generated only modest share price moves.
Regulatory & Risk Context
Invivyd has an effective Form S-3 shelf filed on 2025-10-02, with at least two takedowns via 424B5 supplements in November 2025. The shelf references PEMGARDA and pipeline assets such as VYD2311, and provides pre-approved flexibility for future securities offerings, which can be used alongside other financing tools at the company’s discretion.
Market Pulse Summary
The stock moved -5.4% in the session following this news. A negative reaction despite the largely routine nature of these inducement grants would fit a pattern where secondary or administrative updates draw outsized selling in a stock already trading below its 200-day MA. The announcement covers 731,000 options at a $1.52 exercise price with standard four-year vesting. Given prior capital raises and existing registration capacity, some holders may interpret ongoing equity awards as incremental dilution risk, even without an immediate financing event.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
The options have a per share exercise price of
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
